We are live on ! Find out more
TGI

TRV GP II Portfolio holdings

AUM $1.34M
1-Year Est. Return 67.55%
This Fund
S&P 500
This Quarter Est. Return
-36.53%
1 Year Est. Return
-67.55%
3 Year Est. Return
-20.84%
5 Year Est. Return
-49.87%
10 Year Est. Return
AUM
$93.1M
AUM Growth
-$3.81M
Cap. Flow
+$52.9M
Cap. Flow %
56.76%
Top 10 Hldgs %
100%
Holding
3
New
1
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$52.9M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JNCE
1
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$48.6M 52.19%
10,230,349
RVMD icon
2
Revolution Medicines
RVMD
$40.2B
$41.8M 44.93%
+1,909,317
New +$52.9M
ALNA
3
DELISTED
Allena Pharmaceuticals
ALNA
$2.69M 2.89%
2,790,964

Similar funds

TRV GP II's Q1 2020 Portfolio in Review

As of Q1 2020, TRV GP II held 3 positions worth $93.1M, down 3.9% from $96.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP II deployed $52.9M of net new capital in Q1 2020, opening 1 new position. Its largest new stake was Revolution Medicines: 1,909,317 shares worth $41.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP II's largest Q1 2020 buy was Revolution Medicines: 1,909,317 shares worth $41.8M.
  • TRV GP II's ten largest holdings make up 100% of its $93.1M portfolio in Q1 2020.
  • TRV GP II opened 1 new position and closed 0 in Q1 2020.
  • TRV GP II's portfolio value fell 3.9% quarter-over-quarter to $93.1M.

Based on TRV GP II's 13F filing for Q1 2020, filed 11 May 2020.